AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

The White House cited data showing brand-name drugs in the United States are up to three times more expensive than identical drugs in other developed nations.

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...

Soriot’s latest remarks came as the CEO trumpeted a “very encouraging” start to 2023. The drugmaker delivered total revenues of around $10.9 billion over the first three months of the year ...

This morning in New York, new AstraZeneca chief executive Pascal Soriot is telling investors how he is going to turn around the company that has had the absolute worst track record in research and ...